Literature DB >> 29143812

The NLRP3 inflammasome in acute myocardial infarction.

Stefano Toldo1,2,3, Antonio Abbate1,2.   

Abstract

The heart is extremely sensitive to ischaemic injury. During an acute myocardial infarction (AMI) event, the injury is initially caused by reduced blood supply to the tissues, which is then further exacerbated by an intense and highly specific inflammatory response that occurs during reperfusion. Numerous studies have highlighted the central role of the NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome in this process. The inflammasome, an integral part of the innate immune system, is a macromolecular protein complex that finely regulates the activation of caspase 1 and the production and secretion of powerful pro-inflammatory cytokines such as IL-1β and IL-18. In this Review, we summarize evidence supporting the therapeutic value of NLRP3 inflammasome-targeted strategies in experimental models, and the data supporting the role of the NLRP3 inflammasome in AMI and its consequences on adverse cardiac remodelling, cytokine-mediated systolic dysfunction, and heart failure.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29143812     DOI: 10.1038/nrcardio.2017.161

Source DB:  PubMed          Journal:  Nat Rev Cardiol        ISSN: 1759-5002            Impact factor:   32.419


  90 in total

1.  Interleukin-1 Blockade in Acute Decompensated Heart Failure: A Randomized, Double-Blinded, Placebo-Controlled Pilot Study.

Authors:  Benjamin W Van Tassell; Nayef A Abouzaki; Claudia Oddi Erdle; Salvatore Carbone; Cory R Trankle; Ryan D Melchior; Jeremy S Turlington; Clinton J Thurber; Sanah Christopher; Dave L Dixon; Daniel T Fronk; Christopher S Thomas; Scott W Rose; Leo F Buckley; Charles A Dinarello; Giuseppe Biondi-Zoccai; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2016-06       Impact factor: 3.105

2.  Inflammasome activators induce interleukin-1α secretion via distinct pathways with differential requirement for the protease function of caspase-1.

Authors:  Olaf Gross; Amir S Yazdi; Christina J Thomas; Mark Masin; Leonhard X Heinz; Greta Guarda; Manfredo Quadroni; Stefan K Drexler; Jurg Tschopp
Journal:  Immunity       Date:  2012-03-23       Impact factor: 31.745

Review 3.  NLRP3 inflammasome as a novel player in myocardial infarction.

Authors:  Masafumi Takahashi
Journal:  Int Heart J       Date:  2014-03-14       Impact factor: 1.862

4.  A novel pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury after ischemia-reperfusion in the mouse.

Authors:  Carlo Marchetti; Jeremy Chojnacki; Stefano Toldo; Eleonora Mezzaroma; Nicla Tranchida; Scott W Rose; Massimo Federici; Benjamin W Van Tassell; Shijun Zhang; Antonio Abbate
Journal:  J Cardiovasc Pharmacol       Date:  2014-04       Impact factor: 3.105

5.  A role for mitochondria in NLRP3 inflammasome activation.

Authors:  Rongbin Zhou; Amir S Yazdi; Philippe Menu; Jürg Tschopp
Journal:  Nature       Date:  2010-12-01       Impact factor: 49.962

6.  Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta.

Authors:  B J Pomerantz; L L Reznikov; A H Harken; C A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

7.  Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies).

Authors:  Antonio Abbate; Michael Christopher Kontos; Nayef Antar Abouzaki; Ryan David Melchior; Christopher Thomas; Benjamin Wallace Van Tassell; Claudia Oddi; Salvatore Carbone; Cory Ross Trankle; Charlotte Susan Roberts; George Herman Mueller; Michael Lucas Gambill; Sanah Christopher; Roshanak Markley; George Wayne Vetrovec; Charles Anthony Dinarello; Giuseppe Biondi-Zoccai
Journal:  Am J Cardiol       Date:  2014-11-13       Impact factor: 2.778

8.  Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study).

Authors:  Benjamin Wallace Van Tassell; Ross Arena; Giuseppe Biondi-Zoccai; Justin McNair Canada; Claudia Oddi; Nayef Antar Abouzaki; Arehzo Jahangiri; Raquel Appa Falcao; Michael Christopher Kontos; Keyur Bharat Shah; Norbert Felix Voelkel; Charles Anthony Dinarello; Antonio Abbate
Journal:  Am J Cardiol       Date:  2013-10-04       Impact factor: 2.778

Review 9.  Targeting interleukin-1 in heart disease.

Authors:  Benjamin W Van Tassell; Stefano Toldo; Eleonora Mezzaroma; Antonio Abbate
Journal:  Circulation       Date:  2013-10-22       Impact factor: 29.690

10.  Tumor necrosis factor alpha and interleukin 1beta are responsible for in vitro myocardial cell depression induced by human septic shock serum.

Authors:  A Kumar; V Thota; L Dee; J Olson; E Uretz; J E Parrillo
Journal:  J Exp Med       Date:  1996-03-01       Impact factor: 14.307

View more
  159 in total

1.  Inflammation and NLRP3 Inflammasome Activation Initiated in Response to Pressure Overload by Ca2+/Calmodulin-Dependent Protein Kinase II δ Signaling in Cardiomyocytes Are Essential for Adverse Cardiac Remodeling.

Authors:  Takeshi Suetomi; Andrew Willeford; Cameron S Brand; Yoshitake Cho; Robert S Ross; Shigeki Miyamoto; Joan Heller Brown
Journal:  Circulation       Date:  2018-11-27       Impact factor: 29.690

Review 2.  Anticytokine Agents: Targeting Interleukin Signaling Pathways for the Treatment of Atherothrombosis

Authors:  Paul M Ridker
Journal:  Circ Res       Date:  2019-02       Impact factor: 17.367

Review 3.  Innate immunity as a target for acute cardioprotection.

Authors:  Coert J Zuurbier; Antonio Abbate; Hector A Cabrera-Fuentes; Michael V Cohen; Massimo Collino; Dominique P V De Kleijn; James M Downey; Pasquale Pagliaro; Klaus T Preissner; Masafumi Takahashi; Sean M Davidson
Journal:  Cardiovasc Res       Date:  2019-06-01       Impact factor: 10.787

Review 4.  Hydrogen sulfide-mediated regulation of cell death signaling ameliorates adverse cardiac remodeling and diabetic cardiomyopathy.

Authors:  Sumit Kar; Tyler N Kambis; Paras K Mishra
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-03-29       Impact factor: 4.733

Review 5.  Inflammation in nonischemic heart disease: initiation by cardiomyocyte CaMKII and NLRP3 inflammasome signaling.

Authors:  Takeshi Suetomi; Shigeki Miyamoto; Joan Heller Brown
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-08-23       Impact factor: 4.733

Review 6.  NLRP3 inflammasome in cancer and metabolic diseases.

Authors:  Bhesh Raj Sharma; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2021-03-11       Impact factor: 25.606

7.  Selective Activation of Cannabinoid Receptor 2 Attenuates Myocardial Infarction via Suppressing NLRP3 Inflammasome.

Authors:  Wen Yu; Guangjun Jin; Jiancheng Zhang; Wei Wei
Journal:  Inflammation       Date:  2019-06       Impact factor: 4.092

Review 8.  Reappraising the role of inflammation in heart failure.

Authors:  Luigi Adamo; Cibele Rocha-Resende; Sumanth D Prabhu; Douglas L Mann
Journal:  Nat Rev Cardiol       Date:  2020-01-22       Impact factor: 32.419

9.  NLRP3 deficiency accelerates pressure overload-induced cardiac remodeling via increased TLR4 expression.

Authors:  Fangfang Li; Hao Zhang; Lu Yang; Hui Yong; Qingqing Qin; Mengtong Tan; Luhong Xu; Kai Liang; Jing Zong; Wenhao Qian
Journal:  J Mol Med (Berl)       Date:  2018-08-29       Impact factor: 4.599

10.  Isofraxidin Alleviates Myocardial Infarction Through NLRP3 Inflammasome Inhibition.

Authors:  Guofan Chen; Xiaozheng Song; Dongming Lin; Peng Xu
Journal:  Inflammation       Date:  2020-04       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.